Ducentis Biotherapeutics Secures £5.9m to Advance Inflammatory Disease Therapies
Ducentis Biotherapeutics Ltd., a Bristol-based preclinical-stage biotechnology company, has successfully raised £5.9m in its latest funding round. The funding, with an allotment date of 20 April 2026 ...